MYC and prostate neoplasm: Our in vivo studies initially revealed that MYC-CaP/CR tumors are resistant to docetaxel chemotherapy, when compared to docetaxel sensitive PC3 [33] and LuCaP23.1 AI [34] prostate tumor models.